WO2013047567A1 - フラビンアデニンジヌクレオチドまたはその塩を有効成分として含有する角膜上皮細胞死の抑制剤 - Google Patents

フラビンアデニンジヌクレオチドまたはその塩を有効成分として含有する角膜上皮細胞死の抑制剤 Download PDF

Info

Publication number
WO2013047567A1
WO2013047567A1 PCT/JP2012/074662 JP2012074662W WO2013047567A1 WO 2013047567 A1 WO2013047567 A1 WO 2013047567A1 JP 2012074662 W JP2012074662 W JP 2012074662W WO 2013047567 A1 WO2013047567 A1 WO 2013047567A1
Authority
WO
WIPO (PCT)
Prior art keywords
corneal epithelial
cell death
epithelial cell
salt
adenine dinucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2012/074662
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
明日香 阪元
雅胤 中村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Priority to SG11201400947XA priority Critical patent/SG11201400947XA/en
Priority to CN201280046826.0A priority patent/CN103826642B/zh
Priority to PH1/2014/500660A priority patent/PH12014500660A1/en
Priority to MYPI2014000895A priority patent/MY185239A/en
Priority to KR1020147009783A priority patent/KR20140082699A/ko
Publication of WO2013047567A1 publication Critical patent/WO2013047567A1/ja
Anticipated expiration legal-status Critical
Priority to IN3350DEN2014 priority patent/IN2014DN03350A/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide

Definitions

  • the present invention is an inhibitor of corneal epithelial cell death containing a flavin adenine dinucleotide (FAD) or a salt thereof (hereinafter collectively referred to as “FAD etc.”) as an active ingredient,
  • the present invention relates to an inhibitor, wherein the corneal epithelial cell death is induced by ultraviolet irradiation.
  • the present invention also relates to a method for suppressing corneal epithelial cell death comprising administering to a patient a pharmaceutically effective amount of FAD or the like, wherein the corneal epithelial cell death is induced by ultraviolet irradiation.
  • Non-patent Document 2 discloses that UV-B induces apoptosis (cell death) of corneal epithelial cells.
  • Document 1 discloses that UV-B leads to corneal epithelial damage, corneal edema, turbidity, and the like.
  • FAD is a coenzyme-type vitamin B 2 that is directly involved in cellular redox, and is known to promote corneal enzyme respiratory metabolism. Furthermore, the Furabitan ® ophthalmic solution 0.05% attachment (Non-Patent Document 3), the disodium salt of FAD is useful for keratitis which is implicated vitamin B 2 deficiency or metabolic disorders It is described that there is.
  • the present inventors conducted extensive research to search for drugs that suppress corneal epithelial cell death induced by ultraviolet irradiation. As a result, flavin adenine dinucleotide disodium salt (hereinafter also referred to as “the present compound”) is prominent.
  • the present invention has been completed by finding that it has an excellent cell death inhibitory effect.
  • the present invention relates to an inhibitor of corneal epithelial cell death containing flavin adenine dinucleotide or a salt thereof (FAD or the like) as an active ingredient, wherein the corneal epithelial cell death is induced by ultraviolet irradiation ( Hereinafter also referred to as “this agent”.
  • Another aspect of the present invention is an inhibitor of corneal epithelial cell death containing FAD or the like as an active ingredient, wherein the corneal epithelial cell death is induced by ultraviolet B wave irradiation.
  • the present agent has a concentration of FAD and the like of 0.01 to 1% (w / v).
  • another aspect of the present invention is the present agent having a concentration of FAD or the like of 0.05% (w / v).
  • the other aspect of this invention is this agent whose dosage form is ophthalmic administration. Moreover, the other aspect of this invention is this agent whose dosage form is an eye drop.
  • the present invention relates to a method for inhibiting corneal epithelial cell death comprising administering to a patient a pharmaceutically effective amount of FAD or the like, wherein the corneal epithelial cell death is induced by ultraviolet irradiation (hereinafter referred to as “ This method is also provided).
  • Another aspect of the present invention is a method for inhibiting corneal epithelial cell death comprising administering a pharmaceutically effective amount of FAD or the like to a patient, wherein the corneal epithelial cell death is induced by ultraviolet B-wave irradiation. Is the method.
  • Another aspect of the present invention is the present method, wherein the concentration of FAD or the like is 0.01 to 1% (w / v).
  • Another embodiment of the present invention is the present method, wherein the concentration of FAD or the like is 0.05% (w / v).
  • the present invention relates to the use of FAD or the like for use in the suppression of corneal epithelial cell death, wherein the corneal epithelial cell death is induced by ultraviolet irradiation (hereinafter also referred to as “first use”). Also provide.
  • Another aspect of the present invention is the use of FAD or the like for use in the suppression of corneal epithelial cell death, wherein the corneal epithelial cell death is induced by ultraviolet B-wave irradiation. .
  • Another aspect of the present invention is the first use of the present invention in which the concentration of FAD or the like is 0.01 to 1% (w / v).
  • Another aspect of the present invention is the first book use in which the concentration of FAD or the like is 0.05% (w / v).
  • the other aspect of this invention is 1st this use whose dosage form is eye drop administration. Moreover, the other aspect of this invention is 1st this use whose dosage form is eyedrops.
  • the present invention relates to the use of FAD or the like for producing an inhibitor of corneal epithelial cell death, wherein the corneal epithelial cell death is induced by ultraviolet irradiation (hereinafter referred to as “second use”). Also provided).
  • Another aspect of the present invention also provides use of FAD or the like for producing an inhibitor of corneal epithelial cell death, wherein the corneal epithelial cell death is induced by ultraviolet B wave irradiation.
  • Another aspect of the present invention is the second use of the present invention in which the concentration of FAD or the like is 0.01 to 1% (w / v).
  • Another aspect of the present invention is the second book use in which the concentration of FAD or the like is 0.05% (w / v).
  • the other aspect of this invention is 2nd this use whose dosage form is eye drop administration.
  • Another aspect of the present invention is the second use, wherein the dosage form is an eye drop.
  • the present invention also provides a method for suppressing corneal epithelial cell death comprising administering a pharmaceutically effective amount of FAD or the like to a patient, wherein the corneal epithelial cell death is induced by ultraviolet irradiation. .
  • the present invention also provides use of FAD or the like for use in suppressing corneal epithelial cell death, wherein the corneal epithelial cell death is induced by ultraviolet irradiation.
  • the present invention also provides use of FAD or the like for producing an inhibitor of corneal epithelial cell death, wherein the corneal epithelial cell death is induced by ultraviolet irradiation.
  • FIG. 2 is a graph showing the survival rate when corneal epithelial cells are treated with the present compound before UV-B irradiation.
  • Flavin adenine dinucleotide is a compound represented by the following formula (1).
  • the salt of flavin adenine dinucleotide is not particularly limited as long as it is a pharmaceutically acceptable salt.
  • Salt with inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid, acetic acid , Fumaric acid, maleic acid, succinic acid, citric acid, tartaric acid, adipic acid, gluconic acid, glucoheptic acid, glucuronic acid, terephthalic acid, methanesulfonic acid, lactic acid, hippuric acid, 1,2-ethanedisulfonic acid, isethionic acid, Organics such as lactobionic acid, oleic acid, pamoic acid, polygalacturonic acid, stearic acid, tannic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, lauryl sulfate
  • the salt of flavin adenine dinucleotide is preferably a sodium salt, particularly preferably a flavin adenine dinucleotide disodium salt represented by the following formula (2).
  • flavin adenine dinucleotide or a salt thereof may take the form of a hydrate or a solvate.
  • the crystalline polymorph Forms and crystal polymorph groups are also within the scope of the present invention.
  • the crystal polymorphism group means that the crystal form changes depending on the conditions and state of production, crystallization and storage of these crystals (including the formulated state in this state). Means the individual crystal forms at each stage and the whole process.
  • Flavin adenine dinucleotide or a salt thereof can be produced according to a usual method in the field of synthetic organic chemistry. Moreover, what is marketed by Sigma etc. can also be used.
  • “suppression of corneal epithelial cell death induced by ultraviolet irradiation” not only means suppressing the decrease in the number of viable corneal epithelial cells induced by ultraviolet irradiation, but also It also means preventing or treating corneal epithelial damage, corneal edema, turbidity, etc. accompanied by a decrease in the number of cells (ie, corneal epithelial cell death).
  • UV light means three kinds of ultraviolet A wave (wavelength: 320 nm to less than 400 nm), ultraviolet B wave (wavelength: 290 nm to less than 320 nm), and ultraviolet C wave (wavelength: 200 nm to less than 290 nm). To do. As explained in the background section, it is known that “ultraviolet B wave (UV-B)” is clinically problematic as an inducer of corneal epithelial cell death.
  • this agent is administered locally to the eye.
  • administration form of this agent include ophthalmic administration (including ophthalmic ointment), subconjunctival administration, intraconjunctival sac administration, subtenon sac administration and the like, and ophthalmic administration is particularly preferable.
  • the dosage form of this agent is not particularly limited as long as it can be used for topical ophthalmic administration, and examples thereof include eye drops, eye ointments, injections, patches, gels, insertion agents, and the like. Is preferred. In addition, these can be prepared using the normal technique currently used widely in the said field
  • DDS drug delivery system
  • the injection is selected as necessary from an isotonic agent such as sodium chloride; a buffering agent such as sodium phosphate; a surfactant such as polyoxyethylene sorbitan monooleate; and a thickener such as methylcellulose.
  • an isotonic agent such as sodium chloride
  • a buffering agent such as sodium phosphate
  • a surfactant such as polyoxyethylene sorbitan monooleate
  • a thickener such as methylcellulose.
  • the intercalating agent is prepared by pulverizing and mixing a biodegradable polymer such as hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxyvinyl polymer, polyacrylic acid and the like together with the compound, and compressing the powder. If necessary, excipients, binders, stabilizers, pH adjusters and the like can be used.
  • a biodegradable polymer such as hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxyvinyl polymer, polyacrylic acid and the like.
  • the preparation for intraocular implant can be prepared using a biodegradable polymer, for example, a biodegradable polymer such as polylactic acid, polyglycolic acid, lactic acid / glycolic acid copolymer, and hydroxypropylcellulose.
  • a biodegradable polymer such as polylactic acid, polyglycolic acid, lactic acid / glycolic acid copolymer, and hydroxypropylcellulose.
  • the dose of this drug can be appropriately changed according to the dosage form, the severity of the symptoms of the patient to be administered, age, weight, doctor's judgment, etc. For example, when an eye drop is selected, 0.005 To 5% (w / v), preferably 0.01 to 1% (w / v), more preferably 0.02 to 0.5% (w / v), still more preferably 0.05% (w / v) Instill 1 to 2 drops of this drug containing FAD at the concentration of v).
  • the concentration of FAD or the like described above can be the concentration of flavin adenine dinucleotide (free form) or the concentration of a flavin adenine dinucleotide salt.
  • this drug can be appropriately changed according to the dosage form, the severity of the symptoms of the patient to be administered, age, weight, doctor's judgment, etc.For example, when an eye drop is selected as the dosage form, It can be administered to the eye topically by dividing it 1 to 10 times a day, preferably 2 to 8 times a day, more preferably 3 to 6 times a day.
  • a method for suppressing corneal epithelial cell death comprising administering a pharmaceutically effective amount of FAD or the like to a patient, wherein the corneal epithelial cell death is induced by ultraviolet irradiation ( This method), use of FAD or the like for use in the suppression of corneal epithelial cell death, wherein the corneal epithelial cell death is induced by ultraviolet irradiation (first use), and corneal epithelial cell death
  • FAD or the like for producing an inhibitor, wherein the corneal epithelial cell death is induced by ultraviolet irradiation (second main use).
  • the definitions of the terms in these inventions are also as described above, and the preferred embodiments are the same as described above.
  • SV40 immortalized human corneal epithelial cells (HCE-T: RIKEN, BioResource Center, Cell No .: RCB2280) were seeded in a 96-well plate (1 ⁇ 10 4 cells / well), and 10% FBS-containing DMEM / F- Cultured for 12 days in 12 media. The next day, the DMEM / F-12 medium containing 10% FBS was added to 0.0125% (w / v) or 0.05% (w / v) flavin adenine dinucleotide disodium salt PBS, 0.5% (w / v). v) Chondroitin sulfate sodium-containing PBS or PBS, and then cultured at 37 ° C.
  • % CS group or“ base group ”.
  • the corneal epithelial cells were irradiated with UV-B (80 mJ / cm 2 ) for about 1 minute.
  • the medium of each group was replaced with DMEM / F-12 medium containing 10% FBS again, and cultured at 37 ° C. for 24 hours.
  • CellTiter96 registered trademark
  • AQueous One Solution Cell Proliferation Assay manufactured by Promega, catalog number: The number of viable cells was measured using G3580
  • the survival rate was calculated according to the following formula 1.
  • the flavin adenine dinucleotide disodium salt and chondroitin sulfate sodium salt used in this test were purchased from Kyowa Hakko Bio Co., Ltd. and Maruha Nichiro Foods, Inc., respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PCT/JP2012/074662 2011-09-27 2012-09-26 フラビンアデニンジヌクレオチドまたはその塩を有効成分として含有する角膜上皮細胞死の抑制剤 Ceased WO2013047567A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SG11201400947XA SG11201400947XA (en) 2011-09-27 2012-09-26 Corneal epithelial cell death inhibitor containing flavin adenine dinucleotide or salt thereof as active ingredient
CN201280046826.0A CN103826642B (zh) 2011-09-27 2012-09-26 含有黄素腺嘌呤二核苷酸或其盐作为有效成分的角膜上皮细胞死亡的抑制剂
PH1/2014/500660A PH12014500660A1 (en) 2011-09-27 2012-09-26 Corneal epithelial cell death inhibitor containing flavin adenine dinucleotide or salt thereof as active ingredient
MYPI2014000895A MY185239A (en) 2011-09-27 2012-09-26 Corneal epithelial cell death inhibitor containing flavin adenine dinucleotide or salt thereof as active ingredient
KR1020147009783A KR20140082699A (ko) 2011-09-27 2012-09-26 플라빈 아데닌 디뉴클레오티드 또는 그의 염을 유효 성분으로서 함유하는 각막상피세포사의 억제제
IN3350DEN2014 IN2014DN03350A (enExample) 2011-09-27 2014-04-25

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011210875 2011-09-27
JP2011-210875 2011-09-27

Publications (1)

Publication Number Publication Date
WO2013047567A1 true WO2013047567A1 (ja) 2013-04-04

Family

ID=47995597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/074662 Ceased WO2013047567A1 (ja) 2011-09-27 2012-09-26 フラビンアデニンジヌクレオチドまたはその塩を有効成分として含有する角膜上皮細胞死の抑制剤

Country Status (9)

Country Link
JP (1) JP5969872B2 (enExample)
KR (1) KR20140082699A (enExample)
CN (1) CN103826642B (enExample)
IN (1) IN2014DN03350A (enExample)
MY (1) MY185239A (enExample)
PH (1) PH12014500660A1 (enExample)
SG (2) SG11201400947XA (enExample)
TW (1) TWI561238B (enExample)
WO (1) WO2013047567A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046734A3 (en) * 2014-09-22 2016-06-30 University Of The Western Cape Compounds and compositions for treatment of tuberculosis

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4512395A1 (en) 2023-08-21 2025-02-26 Bio Even Composition comprising flavin adenine dinucleotide (fad), l-gsh, atp and myristic acid, alone or with a drug

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004002358A (ja) * 2002-04-01 2004-01-08 Rohto Pharmaceut Co Ltd 眼科用組成物
JP2004203836A (ja) * 2002-12-26 2004-07-22 Rohto Pharmaceut Co Ltd 眼科用局所適用製剤
JP2005239622A (ja) * 2004-02-26 2005-09-08 Rohto Pharmaceut Co Ltd 角膜障害治療剤
JP2006117656A (ja) * 2004-09-27 2006-05-11 Rohto Pharmaceut Co Ltd ヒアルロン酸又はその塩を含有する粘膜適用組成物
JP2006282586A (ja) * 2005-03-31 2006-10-19 Kobayashi Pharmaceut Co Ltd 眼科用組成物
JP2011137845A (ja) * 2009-12-02 2011-07-14 Rohto Pharmaceutical Co Ltd シリコーンハイドロゲルコンタクトレンズ用眼科組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773076B1 (fr) * 1997-12-29 2000-05-19 Chauvin Lab Sa Utilisation de la flavine-adenine-dinucleotide pour la preparation de compositions ophtalmiques utiles pour le traitement de l'oeil sec
CN101301305A (zh) * 2008-05-14 2008-11-12 北京润德康医药技术有限公司 一种黄素腺嘌呤二核苷酸二钠冻干粉针制剂及其制备方法
EP2735303A1 (en) * 2012-11-23 2014-05-28 Pilosciences Hair growth compositions and methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004002358A (ja) * 2002-04-01 2004-01-08 Rohto Pharmaceut Co Ltd 眼科用組成物
JP2004203836A (ja) * 2002-12-26 2004-07-22 Rohto Pharmaceut Co Ltd 眼科用局所適用製剤
JP2005239622A (ja) * 2004-02-26 2005-09-08 Rohto Pharmaceut Co Ltd 角膜障害治療剤
JP2006117656A (ja) * 2004-09-27 2006-05-11 Rohto Pharmaceut Co Ltd ヒアルロン酸又はその塩を含有する粘膜適用組成物
JP2006282586A (ja) * 2005-03-31 2006-10-19 Kobayashi Pharmaceut Co Ltd 眼科用組成物
JP2011137845A (ja) * 2009-12-02 2011-07-14 Rohto Pharmaceutical Co Ltd シリコーンハイドロゲルコンタクトレンズ用眼科組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ASUKA SAKAMOTO ET AL.: "Effect of Flavin Adenine Dinucleotide on Ultraviolet B Induced Damage in Cultured Human Corneal Epithelial Cells", ABSTRACTS OF 132ND ANNUAL MEETING OF PHARMACEUTICAL SOCIETY OF JAPAN, vol. 3, 5 March 2012 (2012-03-05), pages 180 *
M. NAKAMURA ET AL., FOLIA OPHTHALMOGICA JAPONICA, vol. 47, no. 9, 1996, pages 1082 - 1085 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046734A3 (en) * 2014-09-22 2016-06-30 University Of The Western Cape Compounds and compositions for treatment of tuberculosis

Also Published As

Publication number Publication date
PH12014500660A1 (en) 2014-05-05
KR20140082699A (ko) 2014-07-02
MY185239A (en) 2021-04-30
JP5969872B2 (ja) 2016-08-17
CN103826642B (zh) 2016-02-17
SG10201602401PA (en) 2016-04-28
SG11201400947XA (en) 2014-07-30
JP2013082696A (ja) 2013-05-09
TWI561238B (en) 2016-12-11
IN2014DN03350A (enExample) 2015-06-05
CN103826642A (zh) 2014-05-28
TW201318628A (zh) 2013-05-16

Similar Documents

Publication Publication Date Title
TW201216971A (en) Therapeutic agent for dry eye characterized by the combination of P2Y2 receptor agonist and hyaluronic acid or salts thereof
US9713597B2 (en) Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone
CA2755679A1 (en) Ophthalmic formulations of cetirizine and methods of use
WO2016072440A1 (ja) 眼科用水性組成物
JP5969872B2 (ja) フラビンアデニンジヌクレオチドまたはその塩を有効成分として含有する角膜上皮細胞死の抑制剤
WO2012176865A1 (ja) ヒアルロン酸またはその塩およびプロピレングリコールを含有する点眼液
JP6063191B2 (ja) ヒアルロン酸およびフラビンアデニンジヌクレオチドを組み合わせたことを特徴とする角膜上皮細胞死の抑制剤
WO2010137681A1 (ja) トラニラストを含有する網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、トラニラストまたはその医薬的に許容される塩、ならびにその使用
WO2011149012A1 (ja) イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤、網脈絡膜変性疾患の予防または治療方法、イソキノリンスルホニル誘導体またはその医薬的に許容される塩、ならびにその使用
JP2020514347A (ja) チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤
WO2010010939A1 (ja) 加齢黄斑変性の予防又は治療剤
JP2011225605A (ja) 点眼剤
JP4779382B2 (ja) 点眼剤用組成物
KR20150090045A (ko) 피나플록사신 현탁 조성물
HK1193349B (en) Inhibitor for corneal epithelial cell death, inhibitor characterized by combining hyaluronic acid and flavin adenine dinucleotide
ES2377342T3 (es) Remedio para enfermedades corneales
KR102790252B1 (ko) 각막 손상 또는 안구건조증 예방 또는 치료용 조성물
TW201605451A (zh) 老年性黃斑部病變之預防或治療劑
KR20250073259A (ko) Trpv1 길항제의 결정질 다형체 형태 및 그의 제제

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201280046826.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12836892

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12014500660

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20147009783

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 12836892

Country of ref document: EP

Kind code of ref document: A1